CD4 and breast carcinoma: Furthermore, compared with that in the control group, the expression of CCT2 in CD4+ T cells decreased following treatment with exos derived from CCT2-knockdown breast cancer cells, whereas CCT2-overexpressing exos had the opposite effect (Fig. 7E).